Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Nucore Health vs WeightRx

Nucore Health
Graded #367

Lower grade

vs+13.499999999999993
WeightRx
Graded #85

Higher grade

The verdict

WeightRx takes it — 72.1/100 to 58.6/100.

WeightRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. WeightRx is a telehealth provider publishing compounded semaglutide at $250/mo and compounded tirzepatide at $83/mo.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWeightRx +55
36
91
Dose & formulationEven
64
64
Clinical oversightEven
82
82
Labs & monitoringEven
53
53
FulfillmentNucore Health +2
67
65
Contract termsEven
55
55
Nucore Health · left barWeightRx · right bar

The numbers

MetricNucore HealthWeightRx
WeighScore58.6/10072.1/100
GradeCC
Scorecard rank#367#85
Semaglutide$299/mo (starting dose, compounded)$250/mo (compounded)
Tirzepatide$199/mo (microdose tier, compounded)$83/mo (term not published, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Nucore Health

Graded #367 · C

Strengths

  • Physician-owned and LegitScript Certified — strong trust signals
  • Available nationwide in all 50 states
  • Care and pharmacy fulfillment run on OpenLoop Health's licensed network
  • Broad menu — compounded GLP-1, microdose tirzepatide, NAD+, sermorelin, MIC B12

Where it loses points

  • Published pricing is gated behind the intake quiz — no upfront cost shown
  • Legal terms and privacy are posted as downloadable documents, not web pages
  • Compounded GLP-1 is not FDA-approved and prescribed off-label (per their own notice)
  • Longevity and microdose positioning is marketing; evidence varies by use
WeightRx

Graded #85 · C

Strengths

  • The tirzepatide figure is published up front, and it is genuinely low against the field
  • Both molecules are offered
  • No membership charge is advertised alongside the medication rate

Where it loses points

  • The $83 monthly rate is advertised as '$83/month ($997/year)', which is twelve months of it — no month-to-month rate is separately published, and the terms state that a rate is locked for its full term
  • Both product pages linked from the homepage return 404, so the plan terms cannot be read before intake
  • Six- and twelve-month plans are non-refundable, and eligible refunds carry a 5% processing fee
  • No dose strength is published anywhere, so what the $83 buys is not stated
  • The named operator is Twist G Marketing, LLC rather than a clinical entity, and the terms carry a binding arbitration and class-action waiver

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard